The company's RNA-based predictive test, BA100, identifies breast cancer patients who will not respond to standard chemotherapy, reducing wasted treatments and potentially saving the healthcare system $1.4 billion annually. BIOARRAY's proprietary platform and gene expression assay enable the development of predictive tests for cancer treatments and companion diagnostics. The company's BA100 Triple Negative Breast Cancer Stratification Test addresses the unmet medical need for stratification tests in Triple Negative Breast Cancer patients, allowing for personalized treatment options based on likelihood of treatment response.